Genmab/GSK's Arzerra gets EU recommendation for chronic lymphocytic leukaemia
This article was originally published in Scrip
Executive Summary
Genmab/GlaxoSmithKline's anti-CD20 monoclonal antibody drug Arzerra (ofatumumab) has been recommended by the EU's CHMP for patients with refractory chronic lymphocytic leukaemia (CLL).